Elanco Animal Health (ELAN) closed at $25.74 on November 6, 2026, up 8.7% from the previous close, on volume of 10,335,055 shares (30-day average 4,903,933).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 3, 2026 | Put Spread | 18-Dec-2619 : 24 P | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Elanco Earnings Call Highlights Growth and Stronger Outlook
TipRanks (Sat, 7-Nov 7:12 PM ET)
Elanco Non-GAAP EPS of $0.27 beats by $0.07, revenue of $1.27B beats by $60M
Seeking Alpha News (Fri, 6-Nov 6:29 AM ET)
Elanco Animal Health Reports Third Quarter 2026 Results
PRNewswire (Fri, 6-Nov 6:27 AM ET)
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
PRNewswire (Fri, 6-Nov 6:27 AM ET)
Here are the major earnings before the open Friday
Seeking Alpha News (Thu, 5-Nov 6:00 PM ET)
Elanco Q3 2026 Earnings Preview
Seeking Alpha News (Thu, 5-Nov 1:10 PM ET)
Elanco to Participate in UBS Global Healthcare Conference
PRNewswire (Tue, 3-Nov 7:53 AM ET)
Elanco Animal Health Appoints Jamie Preston as Chief People Officer
PRNewswire (Thu, 22-Oct 6:53 AM ET)
Elanco to Participate in BofA Securities Global Healthcare Conference 2026
PRNewswire (Thu, 17-Sep 7:57 AM ET)
PRNewswire (Tue, 15-Sep 6:28 AM ET)
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
Elanco Animal Health trades on the NYSE stock market under the symbol ELAN.
As of November 6, 2026, ELAN stock price climbed to $25.74 with 10,335,055 million shares trading.
ELAN has a beta of -0.06, meaning it tends to be less sensitive to market movements. ELAN has a correlation of 0.00 to the broad based SPY ETF.
ELAN has a market cap of $12.86 billion. This is considered a Large Cap stock.
Last quarter Elanco Animal Health reported $1 billion in Revenue and $.34 earnings per share. This beat revenue expectation by $56 million and exceeded earnings estimates by $.07.
In the last 3 years, ELAN traded as high as $27.98 and as low as $8.02.
The top ETF exchange traded funds that ELAN belongs to (by Net Assets): IJH, VTI, VB, DFSV, VBR.
ELAN has outperformed the market in the last year with a price return of +19.6% while the SPY ETF gained +10.8%. ELAN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +6.4% and +14.3%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
ELAN support price is $23.15 and resistance is $24.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELAN shares will trade within this expected range on the day.
